Combined inhibin and CA125 assays in the detection of ovarian cancer

Clinical Chemistry

Volumn 45, Issue 5, 1999, Pages 651-658

  Robertson, David M ^a   Cahir, Nicholas ^a   Burger, Henry G ^a   Mamers, Pamela ^b   McCloud, Philip I ^b   Pettersson, Kim ^c   McGuckin, Michael ^d  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF TURKU   (Finland)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; INHIBIN;

ANTIGEN RECOGNITION; ARTICLE; CANCER CLASSIFICATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER;

EID: 0032920905     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/45.5.651     Document Type: Article

References (26)

1. 1. Vale WW, Hseuh A, Rivier C, Yu J. The inhibin/activin family of hormones and growth factors. In: Spom MA, Roberts AB, eds. Peptide growth factors and their receptors. Handbook of experimental physiology. Vol. 95. Berlin: Springer.Verlag, 1990:211-48.
2. 2. Burger HG. Inhibin. Reprod Med Rev 1992;1:1-20.
3. 3. Baird DT, Smith KB. Inhibin and related peptides in the regulation of reproduction. Oxf Rev Reprod Biol 1993;15:191-232.
4. 4. Lappohn RE, Burger HG, Bouma J, Bangah M, Krans M, de Bruijn HWA. Inhibin as a marker for granulosa cell tumours. N Engl J Med 1989;321:790-3.
5. 5. Healy DL, Burger HG, Mamers P, Jobling T, Bangah M, Quinn M, et al. Elevated serum inhibin concentrations in postmenopausal women with ovarian tumors. N Engl J Med 1993;329:1539-42.
6. 6. Cooke I, O'Brien MO, Charnock FM, Groome N, Ganesan TS. Inhibin as a marker for ovarian cancer. J Cancer 1995;71:1046-50.
7. 7. Burger HG, Robertson DM, Cahir N, Mamers P, Healy DL, Jobling T, Groome N. Characterization of inhibin immunoreactivity in post-menopausal women with ovarian tumors. Clin Endocrinol 1996;44:413-8.
8. 8. Lambert-Messerlian GM, Steinhoff M, Zheng W, Canick JA, Gajewski WH, Seifer DB, Schneyer A. Multiple immunoreactive inhibin proteins in serum from postmenopausal women with epithelial ovarian cancer. Gynecol Oncol 1997;65:512-6.
9. 9. Robertson D, Burger HG, Sullivan J, Cahir N, Groome N, Poncelet E, et al. Biological and immunological characterisation of inhibin forms in human plasma. J Clin Endocrinol Metab 1996;81:669-76.
10. 10. Robertson DM, Cahir N, Findlay JK, Burger HG, Groome N. The biological and immunological characterisation of inhibin A and B forms in human follicular fluid and plasma. J Clin Endocrinol Metab 1997;82:889-96.
11. 11. Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309:883-7.
12. 12. Bast RC Jr, Knauf S, Epenetos A, Dhokia B, Daly L, Tanner M, et al. Coordinate elevation of serum markers in ovarian cancer but not benign disease. Cancer 1991;68:1758-63.
13. 13. van der Burg MEL, Lammes FB, Verweij J. CA125 in ovarian cancer. Neth J Med 1992;40:36-51.
14. 14. Robertson DM, Tsonis CG, McLachlan RI, Handelsman DJ, Leask R, Baird DT, et al. Comparison of inhibin immunological and in vitro biological activities in human serum. J Clin Endocrinol Metab 1988;67:438-48.
15. 15. Finney DJ. Statistical method in biological assay. London: Griffin, 1971:668 pp.
16. 16. Hanley JA, McNeil BJ. The meaning and use of the area under a receiving operating characteristic (ROC) curve. Radiology 1982; 143:29-36.
17. 17. Hanley JA, McNeil BJ. A method of comparing the areas under receiving operating characteristic curves derived from the same cases. Radiology 1983;148:839-43.
18. 18. Krzanowski WJ. Principles of multivariate analysis. Oxford: Clarendon Press, 1988:289-306.
19. 19. Shultz EK. Multivariate receiver-operating characteristic curve analysis: prostate cancer screening as an example. Clin Chem 1995;41:1248-55.
20. 20. Petraglia F, Luisi S, Pautier P, Sabourin J-C, Rey R, Lhomme C, Bidart J-M. Inhibin B is the major form of inhibin-activin family secreted by granulosa cell tumours. J Clin Endocrinol Metab 1998;83:1029-32.
21. 21. Robertson DM, Cahir N, Burger HG, Mamers P, Groome N. Inhibin forms in serum from postmenopausal women with ovarian cancers. Clin Endocrinol (in press).
22. 22. Groome NP, Illingworth PJ, O'Brien M, Priddle J, Weaver K, McNeilly AS. Quantitation of inhibin Pro-αC-containing forms in human serum by a new ultrasensitive two-site enzyme-linked immunosorbent assay. J Clin Endocrinol Metab 1996;80:2926-32.
23. 23. Stenman U-H, Alfthan H, Vartiainen J, Lehtovirta P. Markers supplementing CA125 in ovarian cancer. Ann Med 1995;27:115-20.
24. 24. Mogensen O, Megensen B, Jakobsen A. Tumour-associated trypsin inhibitor (TATI) and Cancer antigen 125 (CA 125) in mucinous ovariah tumours. Br J Cancer 1990;61:327-9.
25. 25. Molina R. Ferdeghini M, Chicchio A, et al. Tumour markers in epithelial ovarian cancer: approaches to the interpretation of laboratory data. In: Ballesta A, Torre C, Bombardieri E, Gion M, Molina R, eds. Updating on tumour markers in tissues and in biological fluids. Torino: Edizione Minerva Meddica, 1993:725-35.
26. 26. Gadducci A, Ferdeghini M, Prontera C, Moretti L, Mariani G, Bianchi R, Floretti P. The concomitant determination of different tumour markers in patients with epithelial cancer and benign ovarian masses: relevance for differential diagnosis. Gynecol Oncol 1992;44:147-54.